Screening Program for Heart and Metabolic Health in Early Stage Breast Cancer Survivors

What this Trial Is About

Researchers are evaluating a cardiometabolic screening program designed for women who have survived early stage breast cancer. This program aims to identify common health issues such as prediabetes, diabetes, dyslipidemia, hyperlipidemia, and overweight or obesity after cancer treatment. It also seeks to assess cardiovascular risk factors including smoking, family history, and hypertension, and to compare these findings with healthy individuals matched by age and other conditions. The program includes several steps starting with a prescreening survey about demographics, smoking, and cardiovascular health. Participants then complete consent and baseline assessments including quality of life questionnaires and laboratory tests for blood sugar and cholesterol if recent results are unavailable or abnormal. Based on measurements like BMI, HbA1c, and lipid panels, participants may be referred to specific institutional programs for weight management, endocrinology, or cardiovascular disease prevention. Follow-up assessments occur at 6 and 12 months to track changes in lab values, weight, and patient-reported outcomes. Participants engage in surveys, lab tests, and quality of life questionnaires at the start and during follow-up visits at 6 and 12 months. Researchers collect data on blood sugar levels, cholesterol, weight, and symptoms related to breast cancer and overall health. Referrals to specialized programs are made based on screening results. The study will monitor the prevalence of cardiometabolic conditions and the impact of referrals over a 3-year period, with total participation lasting up to three years to observe long-term health outcomes.

Cardiometabolic Screening Program